Research and Markets (http://www.researchandmarkets.com/research/n8nrcs/equine) has announced the addition of the "Equine Encephalitis - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Equine Encephalitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Equine Encephalitis and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Equine Encephalitis Overview
  3. Therapeutics Development
  4. Pipeline Products for Equine Encephalitis - Overview
  5. Pipeline Products for Equine Encephalitis - Comparative Analysis
  6. Equine Encephalitis - Therapeutics under Development by Companies
  7. Equine Encephalitis - Therapeutics under Investigation by Universities/Institutes
  8. Equine Encephalitis - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Equine Encephalitis - Products under Development by Companies
  13. Equine Encephalitis - Products under Investigation by Universities/Institutes
  14. Equine Encephalitis - Companies Involved in Therapeutics Development
  • Akshaya Bio Inc.
  • AltraVax Inc.
  • EpiVax, Inc.
  • Karyopharm Therapeutics, Inc.
  • Profectus BioSciences, Inc.
  • PsiOxus Therapeutics Limited

For more information visit http://www.researchandmarkets.com/research/n8nrcs/equine